Alzheimer’s disease prevalence is fueling the Leqembi Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Leqembi Market Expected To Change Between 2026 And 2030?

Historical expansion was spurred by the rising incidence of Alzheimer’s disease, coupled with developments in monoclonal antibody research, heightened understanding of the importance of early diagnosis, the broadening of neurology specialty care, and regulatory clearances for targeted therapies.

Anticipated growth during the forecast period is expected to arise from increased investments in neurodegenerative disease research, the rising embrace of early diagnostic instruments, the expansion of personalized Alzheimer’s treatment protocols, a growing concentration on decelerating disease progression, and enhanced payer coverage for innovative therapies. Concurrently, prominent trends anticipated in the forecast period include the increasing adoption of therapies targeting amyloid, a heightened focus on early-stage Alzheimer’s interventions, an escalating demand for disease-modifying neurodegenerative treatments, the broadened application of biomarker-guided patient selection, and improved monitoring of cognitive outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

Which Major Factors Are Driving The Expansion Of The Leqembi Market?

The rising incidence of Alzheimer’s disease is significantly influencing the leqembi market. Alzheimer’s is a progressive neurodegenerative condition impacting memory, cognitive abilities, and behavior, thereby disrupting daily life. This intricate disorder arises from a combination of genetic, lifestyle, and environmental factors. Leqembi works by diminishing beta-amyloid plaques in the brain, thereby assisting in mitigating cognitive deterioration in individuals with early Alzheimer’s disease through plaque targeting and the preservation of memory and cognitive functions. For example, data from September 2024 by the European Brain Council, an international health organization based in Belgium, indicates that around 7 million people in Europe currently suffer from Alzheimer’s disease, a figure projected to reach 14 million by 2030, primarily due to an aging demographic, thus posing a substantial global public health issue. Consequently, the increasing occurrence of Alzheimer’s disease is stimulating expansion within the leqembi market. A key company operating in the leqembi market is concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to lessen how often individuals with Alzheimer’s disease need administration. An intravenous (IV) maintenance dosing regimen entails delivering a steady or repeated dose of medication directly into the bloodstream to maintain therapeutic concentrations for an extended period. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical company based in Japan, and Biogen Inc., a biotechnology company from the US, revealed that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing approach. This therapy specifically targets harmful amyloid proteins, particularly protofibrils, which are thought to play a role in the cognitive decline associated with Alzheimer’s disease (AD). LEQEMBI has demonstrated both clinical and biomarker advantages, including prolonging treatment effectiveness, potentially decreasing neuronal damage, and enhancing patient outcomes over the long term.

How Is The Leqembi Market Structured Across Different Segments?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Which Major Players Dominate The Leqembi Market?

Major companies operating in the leqembi market are Eisai Co. Ltd.

Read the full leqembi market report here:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Region Currently Holds The Largest Share Of The Leqembi Market?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqembi Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20142&type=smp

Browse Through More Reports Similar to the Global Leqembi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795